Platelet-active drugs: the relationships among dose, effectiveness, and side effects.
Patrono
C
C
Univ degli Studi GD'Annunzio, Chieti, Italy.
Coller
B
B
Dalen
J E
JE
Fuster
V
V
Gent
M
M
Harker
L A
LA
Hirsh
J
J
Roth
G
G
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013988:Ticlopidine / Q000009:adverse effects / Q000627:therapeutic use
D016861:Cyclooxygenase Inhibitors; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D004176:Dipyridamole; D013988:Ticlopidine; D001241:Aspirin